Is Aptevo Therapeutics Inc. (APVO) a Buy, Sell, or Hold?
Aptevo Therapeutics Inc.
NASDAQ:APVO
$4.62 USD
$0.47 (11.33%)
- Volume
- 80.53K
- Average Volume
- 55.58K
- Market Capitalization
- $10.1M
- P/E Ratio
- -0.01
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $59.40
- Year Low
- $3.68
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.36
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jeffrey G. Lamothe |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | APVO |
| CUSIP | 03835L702 |
| CIK | 0001671584 |
| Web | https://www.aptevotherapeutics.com |
| Phone | 206 838 0500 |
| Currency | USD |
| Employees | 33 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.38 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.36 |
| Quick Ratio | 3.36 |
| Cash Ratio | 3.05 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -25.44 |
| Price / Cash Flow | -0.37 |
| Price / Book | 0.42 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-87.27 |
| Trailing P/E Ratio | -0.01 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-25.97M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -198.50% |
| Return on Assets | -131.93% |
Financials Score
| AltmanZ Score | -22.84 |
| Piotroski Score | 1.00 |
| Working Capital | 11.22M |
| Total Assets | 19.9M |
| Ebit | -26.26M |
| Market Cap | 9.27M |
| Total Liabilities | 8.29M |
Poll Results
About Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also adva ... ncing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
2026-06-30 08:05:00
SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced it has been awarded a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund under its Implementation and Outcomes Research program to support investigational new drug (IND)-enabling work for APVO451, Aptevo's novel trispecific antibody-like immunotherapy candidate for solid tumors. Aptevo believes that obtaining this competitive award, reviewed by subject matter experts and awarded based on merit, provides external validation of APVO451's tumor-directed trispecific design and supports Aptevo's ongoing work around nectin-4-targeted therapies.
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.
2026-05-28 08:05:00
Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the appointment of Mary J. Janatpour, Ph.D.
2026-05-27 08:05:00
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, and Niowave, Inc., a leader in radioisotope production and supply with established partnerships across the radiopharmaceutical ecosystem, today announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. Niowave made an at-the-market equity investment in Aptevo at closing, representing an initial ownership position of 7.9%,[1] with the potential to build a meaningful equity stake of up to 19.99% through warrant exercises at a premium to the initial purchase and future purchases of Aptevo common stock.
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
2026-05-20 13:01:21
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2026-05-13 08:05:00
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients Executive leadership transition complete. Jeff Lamothe appointed CEO; Marvin White assumes Executive Chair $60 million equity line of credit enhances financial flexibility and extends access to capital through achievement of key catalysts into 2029 SEATTLE, WA / ACCESS Newswire / May 13, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided a business update.
2026-05-06 08:05:00
Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO) today reported new clinical results from its RAINIER frontline acute myeloid leukemia (AML) trial. The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year.
Frequently Asked Questions
-
What is the current Aptevo Therapeutics Inc. (APVO) stock price?
-
Aptevo Therapeutics Inc.(NASDAQ:APVO) stock price is $4.62 in the last trading session. During the trading session, APVO stock reached the peak price of $59.4 while $3.68 was the lowest point it dropped to. The percentage change in APVO stock occurred in the recent session was 11.33% while the dollar amount for the price change in APVO stock was $0.47.
-
APVO's industry and sector of operation?
-
The NASDAQ listed APVO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APVO?
-
Marvin L. White | Executive Chair
Mary J. Janatpour | Senior VP & Chief Scientific Officer
SoYoung Kwon | Corporate Secretary, Senior Vice President, General Counsel, Business Development & Corporate Affairs
Daphne L. Taylor | Senior Vice President & Chief Financial Officer
Dirk Huebner | Senior Vice President & Chief Medical Officer -
How many employees does APVO have?
-
Number of APVO employees currently stands at 33. APVO operates from 2401 4th Avenue, Seattle, WA 98121, US.
-
Link for APVO official website?
-
Official Website of APVO is: https://www.aptevotherapeutics.com
-
How do I contact APVO?
-
APVO could be contacted at phone #206 838 0500 and can also be accessed through its website. APVO operates from 2401 4th Avenue, Seattle, WA 98121, US.
-
How many shares of APVO are traded daily?
-
The average number of APVO shares traded daily for last 3 months was 55.58K.
-
What is the market cap of APVO currently?
-
The market value of APVO currently stands at $10.1M with its latest stock price at $4.62